logo

For the Inventor, By the Inventor

IS

Decode Genetics Ehf


USPTO Granted Patents = 49



Forward Citations = 448

Loading Chart...
Loading Chart...

71 inventors (with patents filed for the assignee):

goldMedal Mark E Gurney (15 out of 59 patents)

silverMedal Jasbir Singh (12 out of 29 patents)

bronzeMedal Vincent Premaratna Sandanayaka (10 out of 41 patents)

4.  Patrick Sulem (7 out of 7 patents)

5.  Hakon Gudbjartsson (7 out of 7 patents)

6.  Hakon Hakonarson (5 out of 44 patents)

7.  Jeffrey R Gulcher (5 out of 5 patents)

8.  Agust Sverrir Egilsson (5 out of 5 patents)

9.  Daniel Gudbjartsson (4 out of 4 patents)

10.  Anna Helgadottir (4 out of 5 patents)

11.  Peng Yu (4 out of 5 patents)

12.  Alexander Kiselyov (3 out of 11 patents)

13.  Georgeta Hategan (3 out of 13 patents)

14.  David E Zembower (3 out of 15 patents)

15.  Alex Burgin (3 out of 4 patents)


Core Competencies:
Genetic Susceptibility Variants
Cardiovascular Disease
Breast Cancer Risk Assessment
Inflammatory Disorders
Prostate Cancer Risk
Diabetes Mellitus
Atrial Fibrillation
LTA4H Inhibitors
Ex Vivo Models
Drug Sensitivity Prediction
Human Osteoporosis Gene
Human Narcolepsy Gene

49 patents:

1. 9617597 - Genetic susceptibility variants associated with cardiovascular disease (2017-04-11),
2. 8951735 - Genetic variants for breast cancer risk assessment (2015-02-10),
3. 8883833 - Substituted benzoazole PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders (2014-11-11),
4. 8877816 - 4-(or 5-) substituted catechol derivatives (2014-11-04),
5. 8865400 - Genetic variants contributing to risk of prostate cancer (2014-10-21),
6. 8828657 - Susceptibility variants for lung cancer (2014-09-09),
7. 8808985 - Susceptibility variants for peripheral arterial disease and abdominal aortic aneurysm (2014-08-19),
8. 8796182 - Genetic markers associated with risk of diabetes mellitus (2014-08-05),
9. 8795963 - Genetic markers for risk management of atrial fibrillation and stroke (2014-08-05),
10. 8791267 - Biaryl PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders (2014-07-29),
11. 8697360 - Genetic variants on CHR 11Q and 6Q as markers for prostate and colorectal cancer predisposition (2014-04-15),
12. 8637244 - Genetic markers for risk management of atrial fibrillation, atrial flutter, and stroke (2014-01-28),
13. 8598359 - Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation (2013-12-03),
14. 8580501 - Genetic variants on chr 5p12 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment (2013-11-12),
15. 8367333 - Genetic variants as markers for use in diagnosis, prognosis and treatment of eosinophilia, asthma, and myocardial infarction (2013-02-05),
deCode Genetics is a biopharmaceutical company based in Reykjavik, Iceland. They specialize in human genetics and use genomic information to develop novel diagnostic tests and discover new drugs for various diseases. Their research focuses on identifying genetic markers associated with complex diseases such as cancer, cardiovascular disorders, and neurological conditions. Through their extensive genetic database and advanced analytical tools, deCode Genetics aims to advance personalized medicine and improve patient outcomes.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

...
49 Patents

#1 in

#3 in Iceland

#13,856 in the World

...
IS

Decode Genetics Ehf

Forward Citations = 448

71 inventors:

goldMedal Mark E Gurney (15 out of 59 patents)

silverMedal Jasbir Singh (12 out of 29 patents)

bronzeMedal Vincent Premaratna Sandanayaka (10 out of 41 patents)

4.  Patrick Sulem (7 out of 7 patents)

5.  Hakon Gudbjartsson (7 out of 7 patents)

Please report any incorrect information to support@idiyas.com
Loading…